Biosimilars: Experts Discuss Possible Interchangeability Guidance Changes and Reducing Phase 3 Requirements

Biosimilars: Experts Discuss Possible Interchangeability Guidance Changes and Reducing Phase 3 Requirements

Source: 
RAPS.org
snippet: 

With a mountain of challenges to creating sustainable biosimilars markets, particularly in the US, experts on Friday at the Medicines for Europe’s 16th annual biosimilars conference in London discussed possible regulatory changes that could help open the doors for more competitors.